Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant decrease in short interest in the month of March. As of March 13th, there was short interest totaling 10,571 shares, a decrease of 81.0% from the February 26th total of 55,704 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average trading volume of 193,015 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 193,015 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.4% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $1.00 target price (down from $3.00) on shares of Virax Biolabs Group in a research note on Friday, January 9th. Zacks Research raised Virax Biolabs Group to a “hold” rating in a report on Tuesday, January 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Virax Biolabs Group in a research report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Virax Biolabs Group currently has an average rating of “Hold” and a consensus price target of $1.00.

Virax Biolabs Group Trading Up 0.7%

NASDAQ:VRAX traded up $0.00 during mid-day trading on Tuesday, hitting $0.18. The stock had a trading volume of 281,210 shares, compared to its average volume of 227,252. The company has a 50 day simple moving average of $0.23 and a 200-day simple moving average of $0.42. Virax Biolabs Group has a 52 week low of $0.17 and a 52 week high of $1.35.

Virax Biolabs Group Company Profile

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.